GlassScriptPhysician profile
Brian R Osler
NPI 1619469095
$10,280.88
in general payments reported to CMS, 2019-2025
23 companies · $6,054 in 2025
The $6,054 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $879 · 2023: $1,935 · 2024: $1,414 · 2025: $6,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,266 · Travel and Lodging: $2,622 · Education: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,265.95 |
| Travel and Lodging | $2,621.52 |
| Education | $514.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,626.84 | 2023-2025 | Mitraclip, Navitor, Ensite |
| Medtronic, INC. | $1,981.36 | 2023-2025 | Symplicity G3, Corevalve Evolut R, Turbohawk |
| Actelion Pharmaceuticals US, INC. | $983.83 | 2023-2025 | Opsumit, Uptravi |
| Boston Scientific Corporation | $728.96 | 2024-2025 | Avvigo Guidance System |
| Abiomed | $473.27 | 2022-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $340.15 | 2022-2025 | |
| Shockwave Medical, INC | $264.06 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $245.63 | 2022-2024 | Xarelto |
| Novo Nordisk INC | $243.37 | 2022-2024 | Wegovy |
| Pfizer INC. | $220.64 | 2022-2025 | |
| Amgen INC. | $156.99 | 2023-2025 | Repatha, Repatha |
| Cardiva Medical, INC. | $144.98 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Ancora Heart, INC. | $134.47 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $126.10 | 2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $122.67 | 2022-2024 | Camzyos, Eliquis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $108.80 | 2022 | |
| Teleflex LLC | $97.86 | 2023-2024 | Guideliner |
| Impulse Dynamics (USA) INC. | $90.84 | 2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.81 | 2024-2025 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $63.78 | 2023 | Arcalyst |
| Philips North America LLC | $23.61 | 2024 | (9266) Elca |
| Penumbra, INC. | $22.27 | 2025 | Penumbra System |
| Astrazeneca Pharmaceuticals LP | $14.59 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Osler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.